Background—The therapeutic effects of nonspecific β-blockers are limited by
vasoconstriction, thus justifying the interest in molecules with ancillary vasodilating …

Background—Nebivolol is a β1-selective adrenergic receptor antagonist with proposed nitric
oxide (NO)–mediated vasodilating properties in humans. In this study, we explored whether …

Background—Coronary vessel tone is modulated in part by β-adrenergic relaxation.
However, the implication of specific β-adrenoceptor subtypes and their downstream …

Nebivolol is a highly selective β 1 adrenoceptor blocker with additional vasodilating
properties. Although it has been shown that the nebivolol-induced vasorelaxation is nitric …

Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Nebivolol is a highly selective β1-adrenergic receptor antagonist that also possesses
vasodilator properties that are attributed largely to nitric oxide (NO). The objective of the …

Nebivolol is a β1-adrenergic receptor antagonist that also reduces blood pressure by
evoking endothelial NO production and vasodilation. We aimed at assessing whether …

Nebivolol, a selective β‐adrenoceptor (β1‐AR) antagonist, induces vasodilatation by an
endothelium‐and NO‐cGMP‐dependent pathway. However, the mechanisms involved in …

Nebivolol is a recently developed β-blocker provided with vasodilator properties. Because
the mechanism of the putative endothelium-dependent effect of this β-adrenoceptor blocker …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …